Posted by
Arun Shastri on Mon, Jan 27, 2020
This blog post is the seventh in a series on the impact that AI will have on different business aspects of pharma.
Real world data (RWD) is as old as data itself. It was relatively useless, however, until it was digitized. And then once it was digitized, we struggled to analyze so much data at scale with any kind of efficiency.
Enter our ability to store and analyze large volumes of data and advancements in data science, algorithms and technology. With the help of AI, it’s now possible to truly leverage RWD and begin to understand patient populations in holistic ways that have so far eluded pharmaceutical companies. It’s accelerating the use of evidence across healthcare to support the focus on patient health outcomes.
>
Read More
Posted by
Venkat Sethuraman on Wed, Apr 03, 2019
Venkat Sethuraman co-wrote this post with Jessica Rine, Sharma R D and Francine Leech
The 10th-annual Summit for Clinical Operations Executives (SCOPE) took place Feb. 18-21 in Orlando, and it drew more than 3,000 participants from life sciences companies around the world. The conference covered advanced and innovative solutions in clinical trial planning, management and operations.
While the attendees represented different functional areas within clinical operations, they were united around a common question: How can data be used to bring value, provide actionable insights and enhance the clinical trial process?
>
Read More
Posted by
Qin Ye on Thu, Jan 24, 2019
Ishita Srivastava and Divya Babbar co-authored this blog post with Qin Ye.
The FDA considers the use of real-world data and real-world evidence a top strategic priority, and on Dec. 6, it unveiled its much-anticipated RWE framework to support the development of drugs and biologics. The framework is aimed at evaluating the potential use of RWE for assessing a product’s effectiveness and focuses on increased stakeholder engagement to effectively leverage RWD and RWE for public health purposes.
>
Read More
Posted by
ZS Editors on Tue, Sep 04, 2018
Many pharmaceutical companies have realized the benefits of moving from standalone real-world data (RWD) projects to full-fledged, cross-functional real-world evidence (RWE) capabilities to drive everything from their R&D programs to their commercial teams’ efforts to demonstrate value—and technology is central to their success. “Real-world evidence is essentially extracting intelligence out of real-world data, and now that we have the right technology, scalable cloud storage and tremendous processing power, we’re actually able to sift through big data to find those insights,” says Abhay Jha, a principal at ZS and the business technology lead in the firm’s R&D excellence practice.
>
Read More
View All ZS Offices
